NF Trinity Capital’s Teva Pharmaceuticals TEVA Stock Holding History

NF Trinity Capital’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-53,000	Closed	-$817K	–	46
2018 Q4	$817K	Hold	53,000	–	–	0.13%	45
2018 Q3	$1.14M	Hold	53,000	–	–	0.15%	50
2018 Q2	$1.29M	Hold	53,000	–	–	0.18%	54
2018 Q1	$906K	Hold	53,000	–	–	0.12%	54
2017 Q4	$1M	Hold	53,000	–	–	0.13%	52
2017 Q3	$933K	Hold	53,000	–	–	0.13%	45
2017 Q2	$1.76M	Hold	53,000	–	–	0.25%	44
2017 Q1	$1.7M	Hold	53,000	–	–	0.23%	44
2016 Q4	$1.92M	Hold	53,000	–	–	0.27%	42
2016 Q3	$2.44M	Hold	53,000	–	–	0.27%	45
2016 Q2	$2.66M	Hold	53,000	–	–	0.29%	42
2016 Q1	$2.84M	Buy	+53,000	New	+$3.11M	0.34%	39

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NF Trinity Capital's TEVA Position: Q1 2019 in Review

NF Trinity Capital sold out of Teva Pharmaceuticals (TEVA) in Q1 2019, closing a stake of 53,000 shares — an estimated $817K sold.

NF Trinity Capital first reported a position in TEVA in Q1 2016 and held it in 12 quarters. The position peaked at $2.84M in Q1 2016. 521 funds tracked by Wall St. Rank hold TEVA as of Q1 2019.

NF Trinity Capital reported no remaining Teva Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
NF Trinity Capital sold 53,000 Teva Pharmaceuticals shares in Q1 2019, an estimated $817K.
NF Trinity Capital first reported a position in Teva Pharmaceuticals in Q1 2016 and held it in 12 quarters.
NF Trinity Capital's Teva Pharmaceuticals position peaked at $2.84M in Q1 2016.
521 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2019.

Based on NF Trinity Capital's 13F filing for Q1 2019, filed 10 May 2019.